ABSTRACT Globally, lung cancer is responsible for nearly one in five cancer deaths. The National Lung Screening Trial (NLST) demonstrated the efficacy of low-dose computed tomography (LDCT) to identify early-stage disease, setting the basis for widespread implementation of lung cancer screening programs. However, the specificity of LDCT lung cancer screening is suboptimal, with a significant false positive rate. Representing this imaging-based screening process as a sequential decision making problem, we combined multiple machine learning-based methods to learn a partially-observable Markov decision process that simultaneously optimizes lung cancer detection while enhancing test specificity. Using NLST data, we trained a dynamic Bayesian network as an observational model and used inverse reinforcement learning to discover a rewards function based on experts' decisions. Our resultant predictive model decreased the false positive rate while maintaining a high true positive rate at a level comparable to human experts. Our model also detected a number of lung cancers earlier.
I. INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality, estimated to be responsible for 2.1 million deaths worldwide in 2018. Although the five-year survival rate for this disease improves when discovered in its nascent stages [1] , only 15% of all lung cancers are detected early as symptoms often do not appear until the disease has advanced to a late or terminal stage. The findings of the National Lung Screening Trial (NLST) and more recent NELSON study [2] , [3] support the implementation of lung cancer screening programs to identify individuals at high-risk for developing this disease, using low-dose computed tomography (LDCT) imaging to maximize initial detection [2] , [4] . Lung cancer screening guidelines consider the high-risk population as a whole, balancing the benefit of longitudinal observation of pulmonary nodules against pragmatic issues including test sensitivity and specificity. Of current concern is the disproportionately high false positive (FP) rate for LDCT screening: in the NLST,
The associate editor coordinating the review of this article and approving it for publication was Vivek Kumar Sehgal. the overall positive screen rate with LDCT was 24%, yet the positive predictive value of a positive screen was less than 4% [5] . Of the total number of lung nodules diagnosed in the NLST, only 3-6% were found to be malignant, depending on nodule size. The negative consequences of overdetection are significant, increasing the use of unnecessary diagnostic procedures results in complications and patient duress [6] . As such, in this work we present a novel approach that reduces the FP rate associated with LDCT lung cancer screening while maintaining a high true lung cancer detection rate.
Applying computational methods on the growing amount of data available from electronic health records (EHRs) and imaging in this domain, we can address such issues and begin to ask the more precise question of how to optimize lung cancer screening for each person, discovering better ways to risk-stratify as an individual's disease trajectory unfolds. But individually-tailoring this process is not straightforward: the obvious next ''best'' action may not be ideal in the long run given a patient's evolving risk factors, potential future observations, and changing benefit of decisions as time progresses. Sequential decision making, a class of algorithms VOLUME 7, 2019 This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see http://creativecommons.org/licenses/by/4.0/ used in artificial intelligence (AI) for selecting the series of actions optimizing the likelihood of achieving a goal in dynamic environments, provides one way to overcome this difficulty. Known as the temporal credit assignment problem [7] , we pose lung cancer screening in terms of finding the series of actions, given various observations over time, which maximizes early disease detection while minimizing false positives.
We developed a predictive model informing personalized lung cancer screening policies using machine learning and sequential decision making methods. Specifically, we established a framework for learning a partially-observable Markov decision process (POMDP), progressively optimizing the choice of screening actions given prior observations. POMDPs, a generalization of Markov decision processes, are useful when serial observations of a disease are indirect and/or subject to interpretation. Demonstrated in other settings [8] - [11] , the implementation of POMDPs to guide clinical decision making is challenging given the need to derive required probability distributions and reward functions. We leveraged different techniques to learn a POMDP from NLST data: we integrated a dynamic Bayesian network (DBN) into the POMDP to predict the chance of developing lung cancer and to determine the POMDP's observation and transition probabilities, and we applied inverse reinforcement learning (IRL) to formulate a rewards model [12] , mimicking experts' decisions.
We trained and tested our POMDP using a dataset of 5,402 single nodule unique trajectories of lung cancer screening patients from the NLST LDCT trial arm. We compared our model's decisions with experts' decisions over time, and found that: 1) our POMDP lowered the false positive rate for most screenings in the NLST, while maintaining true positive detection rates; and 2) our POMDP improves early prediction of cancer cases with indeterminate pulmonary nodules (IPNs, nodules having some risk of developing into cancer [13] ) as compared to radiologists' interpretation.
II. METHODS

A. NLST DATASET
The NLST was a multi-site randomized controlled trial examining the impact of two imaging modalities, LDCT and chest x-ray, for early detection of lung cancer in asymptomatic, high-risk individuals. Over 53,000 participants underwent three annual screenings with follow-up to assess cancer outcomes. Participants suspected of cancer were referred for diagnostic procedures (e.g., biopsy) and removed from the study for treatment if lung cancer was confirmed. In this work, we used data gathered from NLST's LDCT arm. The dataset comprises over 25,000 participants with information on demographic, clinical, and imaging data. Of this population, only 10,231 cases had one or more solitary IPNs over the study period. Figure 1 shows the number of patients and total number of nodules reported. Unfortunately, NLST annotation data did not uniquely identify individual nodules in participants with multiple nodules, making linking observations over serial scans difficult. As such, we further constrained our data to individuals with only one IPN reported in the same anatomical lung lobe during the study, assuming that the same nodule was observed over time. This selection criteria and preprocessing to remove inconsistent cases (see below) resulted in a total of 5,402 cases, which we used to train and test our POMDP model.
To perform a five-fold stratified cross validation (80 : 20% training:test ratio) with this data, we randomly generated each fold while maintaining the relative proportion of cancer to non-cancer cases seen at each screening time point of the NLST study.
B. DATA PREPROCESSING Table 1 summarizes the NLST variables used in our analysis. We considered the same demographic and clinical variables selected in the Tammemägi model [14] and replicated its preprocessing steps. We converted two variables into binary representations: family history of lung cancer (if any first degree relative had a history of lung cancer) and personal lung cancer history (if the individual had any prior history of lung cancer). Missing values for the variables used with the Tammemägi model were imputed using a variation of a multiple clustering imputation approach [15] . In addition to the radiologist's overall interpretation of the LDCT scan, we employed several imaging features describing the nodule, discretizing continuous variables: location, nodule size (Bin 1: ≥ 0 mm and 3 mm; Bins 2-9: 1 mm bins from 3 − 11 mm; Bin 10: > 11 mm and 27 mm; and Bin 11: > 27 mm), predominant attenuation, and margins. Given the sparsity of cases with nodules of size > 11 mm, we created larger bins by identifying discretizations maximizing POMDP performance using the training data.
We removed inconsistent cases with a perpendicular measurement greater than the reported longest nodule diameter and any cases with missing measurements. Cases without screening abnormalities at an annual screening for reasons other than death, cancer, or missed screening, a nodule size between 0-3 mm was assumed. Cases without nodule size abnormalities across the three annual screenings were excluded from the analysis. Nodule size was then interpolated between annual screenings using the average value between time points, with nodule consistency, margins, and follow-up decisions unchanged relative to the earlier annual observation. This interpolation, used only when training (learning the model's parameters), augmented temporal data points every six month intervals for the training data and improved the overall performance of our POMDP model when testing. Other variables used in the model include the total number of screening days, occurrence of diagnostic VOLUME 7, 2019 procedures (biopsy, thoracotomy, diagnostic CT exam), and confirmed diagnoses of lung cancer. Figure 2 (a) illustrates the lung cancer screening POMDP state space, observations, and potential state transitions. We adopted a state space used in our earlier work [16] . This state space consists of three states defined around the true cancer state of each subject after each screening. No − cancer (NC) is the state in which the individual has no remarkable findings for lung cancer (e.g., nodules < 4 mm). The Uncertain (U) state is an intermediate state in which an individual exhibits suspicious abnormalities (e.g., lung nodules ≥ 4 mm) but no confirmed diagnosis of lung cancer. The LungCancer (LC) state represents any case with a confirmed lung cancer diagnosis through the use of additional procedures. LC is a terminal state in which an individual enters and simultaneously leaves the screening process (as NLST participants diagnosed with lung cancer were removed from the clinical trial for treatment). We simplified the set of possible actions into two types, embodying the core decisions made by experts: to continue screening with a follow-up LDCT or to recommend an intervention (i.e., any procedure performed in relation to diagnosing lung cancer).
C. DEFINING AND LEARNING THE POMDP COMPONENTS 1) STATES (s) AND ACTIONS (a)
2) OBSERVATIONS (z)
Following from the NLST's screening paradigm, two types of observations are possible: those coming from annual screens (LDCT findings) and interpretation and those arising from a diagnostic intervention. To capture the interactions between the nodule size, consistency, and margins we used a model to combine the observations into a single representation as a probability. Specifically, we used a DBN to infer the probability of cancer over time from these observations. Alternative models were considered, including logistic regression, and an exhaustive search of all combinations of observations, with the DBN and the exhaustive search demonstrating the best performance in conjunction with the POMDP (see Appendix Table 17 ). The DBN topology was learned from the data: we learned the intra-slice structure of the DBN (i.e., conditional dependencies between variables in the same time step) using t 0 observations from the K2 algorithm in the Bayes Net Toolbox (BNT) [17] ; and inter-slice structure (i.e., dependencies over time) was learned using cases that had a complete trajectory of screening over the NLST screening period (i.e., no missing observations) using the batch Expectation-Maximization (EM) algorithm also in BNT. Figure 2 (b) shows the intra-and inter-slice structure of the learned model, which we then parameterized using training data. In the POMDP, we then used this DBN with observations of a given patient to infer a probability of cancer over time as our new observation. These probabilistic observations were discretized in 100 equal sized bins, from 0-1. For intervention observations, we determined if an individual undergo an intervention and was diagnosed with cancer or did not undergo an intervention.
3) TRANSITION AND OBSERVATION PROBABILITIES
Transition and observation probabilities were computed using a dynamic Bayesian network, per Figure 2(c): the LDCT node represents a conditional probability table (CPT) of 100 categories corresponding to each discretized probability; the Intervention node represents a CPT table of two observations, cancer after an intervention or no cancer with or without an intervention; and the Cancer node represents a CPT table of three categories per our state model. Usually, the transition probabilities of a POMDP are different based on the choice of action in a given state (T (s j , s i , a)). The transition matrix used for the lung cancer POMDP model is assumed to be invariant of action. But the observation matrix (O(z, s, a)) is state and action dependent. We modeled the observations of Intervention as being impossible (i.e., probability of zero) when the action of LDCT is performed and the observation of an LDCT as impossible when the action of Intervention is performed. An important implementation note is in regards to sparsity, as some LDCT probabilities will be calculated as zero given no instances in the dataset (although they are feasible in real-world settings). Thus, to deal with sparsity we replaced all zero probabilities with a very small probability (0.0001) and normalized over the matrix to improve overall inference [18] .
4) REWARDS
A POMDP's reward function defines the behavior of the agent as it aims to optimize based on returned values. In our POMDP, we define rewards in terms of a state-action pair (R(s,a)). We learned a reward function using the recommendations of experts from the NLST dataset. Using inverse reinforcement learning (IRL), we learned state and action rewards via an adaptive maximum entropy IRL algorithm [12] . A multiplicative model was then employed to learn each combination of state-action pair rewards.
5) INITIAL BELIEFS
In a POMDP, the belief state is a probability distribution over the states of the process. The initial belief is the initial probability distribution over the states at time t 0 . To generate initial beliefs for each individual we used the PLCO M2012 model [14] with demographic and clinical features at baseline to predict the risk of cancer. Tammemägi et al. [19] used the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial to develop 6-year lung cancer risk models. The models achieved high discrimination and calibration performance. The PLCO M2012 is an updated version of the original model trained and validated on the PLCO dataset and externally validated on the NLST cohort. The variables and weights of the logistic regression model used are the same as reported in the PLCO M2012 model [14] . Demographic features include age, education, race, and body mass index (BMI). Clinical features encompassed the presence of chronic obstructive pulmonary disease (COPD), family history of lung cancer, personal history of cancer, smoking status, smoking intensity, and duration of smoking. To generate an initial belief of cancer over the three states of our state space, we used the following rule: the probability of the LC state The magnitude of the effect size of the p-value computed using the Cramer's r 2 , the r 2 , and the Cohen's r 2 are color-coded as: Orange, small effect size ( + ); blue, medium effect size ( ++ ); and black, large effect size ( +++ ). The Cramer's r 2 , the r 2 , and the Cohen's r 2 ranges for small, medium, and large are given in the Appendix.
is the risk of cancer times two computed by the PLCO M2012 model; the probability of the U state is assumed to be zero and the probability of the NC state is the complement of LC. To update beliefs we follow the basic recursive filtering rule [20] , given by Equation 1 where α is a normalization constant such that α = .
D. SOLVING THE POMDP MODEL POMDP models can be solved through the value iteration (VI) algorithm. However, the number of possibilities to be considered is exponential in terms of the number of states, actions, and observations modeled. At each time step, the VI algorithm enumerates k new policies trees, where k is the previous time step number of policy trees and is the number of observations. Each policy tree represents a linear function.
For an infinite horizon process the value function will have infinite linear functions, a key reason why POMDPs are often considered impractical. To solve infinite horizon problems, we can use approximation algorithms [20] - [23] , providing significant speed-up. Markedly, our proposed POMDP model has three states, two actions and 102 observations. We opted to use the QMDP approximation algorithm, shown in Algorithm 1 in the Appendix. QMDP solves the POMDP problem as an MDP and then generalizes the value function into a POMDP. More specifically, the QMDP algorithm estimates the value function for the equivalent MDP while ignoring the observation model. The MDP value function is used to define a linear function (i.e., a policy tree) for each action.
The main disadvantage of the QMDP algorithm is that it dismisses the state uncertainty described in POMDPs but solves the POMDP with MDP computational time complexity. To select optimal actions that maximize expected utility we use Algorithm 2 in the Appendix, which given a belief and the Q matrix computes their dot product to compute the utility of each action when being in a belief (b).
III. RESULTS
NLST participants underwent three annual screenings with follow-up over six years to identify subsequent lung cancers. At each screening time point (t 0 , t 1 , t 2 ), a radiologist read the imaging study and made a decision to refer patients for a diagnostic procedure (e.g., early repeat LDCT, diagnostic CT, PET-CT, or biopsy/tissue sampling) or to continue annual LDCT screening. Our POMDP suggests actions at these three screening time points as well as between the screenings using imputation, resulting in five recommendations in 6-month intervals (Figure 3(a) ). Observations used by the POMDP include imaging features about nodule size, margins, location, and consistency. Our evaluation examines the POMDP's recommended actions over all five points (a POMDP 0 , a POMDP 0.5 , a POMDP 1 , a POMDP 1.5 , a POMDP 2 ) and directly compares against the physicians' performance at the annual screenings.
A. POMDP VERSUS PHYSICIAN PERFORMANCE
To compare the performance of the POMDP model against physicians we calculated the precision (positive predictive value, PPV), recall/true positive (TP) rate (sensitivity), and true negative (TN) rate (specificity) for recommended actions at each screening point. We used the following criteria to assess our model: if the POMDP suggests a diagnostic intervention and the individual is subsequently diagnosed with cancer in the following time period, it is counted as a true positive, otherwise it is considered a false positive; if the POMDP suggests no diagnostic intervention, but an annual LDCT screen, and the individual is diagnosed with cancer in [24] . Tables 5-14 follow the color coding and bolding depicted in Table 4 .
the following screen, it is a false negative (FN), otherwise it is a true negative (Figure 3(b) ). We assessed our POMDP's performance based on a five-fold cross validation design. To match physicians' TP rates (who had a lower threshold for positive screens) and obtain comparable results, we adjusted the POMDP rewards function (using the training data) to be more conservative. We then evaluated this updated POMDP on our testing data. Table 2 shows the results of the POMDP model with tuned rewards against physicians' performance. Our model reduces the FP rate in most screenings (t 1 , t 2 , and post-screening) compared to the experts while maintaining a high TP rate for screening: at t 0 , TN and TP rates are 2% lower and 3% lower than the physicians'; at t 1 , TN and TP rate are 1% higher and 3% higher; at t 2 , TN and TP rate are 4% higher and 4% lower; and in the post-screening period the POMDP's TN and TP rate are 3% higher and 8% higher than the experts', respectively. We also analyzed the performance of the POMDP model for earlier cancer detection (i.e., detection of a t 2 cancer at t 1 ). The detection of early TPs is also improved with earlier diagnostic recommendations (e.g., the TP rate for action a POMDP 0 , a POMDP 0.5 , a POMDP 1 , a POMDP 1.5 for t 2 and post-screening) compared to physicians' recommendations. The POMDP TP rate is higher than the physician's over time for post-screening, as depicted in Figure 5 and discussed in the following section. 
B. UNDERSTANDING POMDP AND PHYSICIAN DIFFERENCES
We calculated a kappa score to test the level of agreement between physicians and the POMDP. Notably, kappa values trended lower, implying that the POMDP and experts classify different cases positively over time, which influences the FP rate. To elucidate this difference, we grouped subjects predicted to have lung cancer by the POMDP vs. physicians, analyzing cases where they had different predictions. The preponderance of subjects different between the groups were individuals classified as FPs or early TP cases (i.e., cases predicted as positives earlier by the POMDP relative to their cancer diagnosis in the NLST trial). Figure 4 depicts these two cohorts. We explored the feature distributions of each group to assess similarity. We used chi-squared or Fisher's tests for categorical variables and the Student or WilcoxonMann-Whitney tests for continuous variables. Additionally, to assess the effect size of the computed p-value we used the Cramer's V and the r 2 or Cohen's r 2 effect size, correspondingly, for each test [24] - [26] . Tests with p-values < 0.05 were considered significant. The false positive analysis showed Table 4 .
that smoking years, age, largest nodule size at t 0 , and smoking quit time had significantly different distributions and the largest effect size between the groups of post-screening cases (see Table 3 ). The additional early prediction TP cases predicted by the POMDP model in comparison with the physicians showed that nodule size at t 0 (largest nodule diameter) and smoking years were significantly different between the groups. The nodule size at t 0 was shorter and years of smoking less than the early TPs predicted by both the physicians and POMDPs (see Table 3 and Figure 4) . A full analysis comparing these groups is presented in the Appendix.
C. POMDP STABILITY
In the NLST, a minimum threshold of 4 mm was used to classify findings as nodules. A later analysis [27] , [28] showed Table 4 .
that changing this threshold to 6 mm significantly reduced the FP rate while maintaining the same TP rate [29] , [30] . As such, we stratified our cases into nodules < 6 and ≥ 6 mm at baseline and tested the POMDP. To assess the robustness and performance distribution of the POMDP model we performed a bootstrap evaluation, randomly sampling from our NLST dataset 240 times to define our training and testing sets. Subsequently, all performance measures for each seed were used to calculate the median, the interquartile range (IQR), and the range for each metric. This analysis is summarized VOLUME 7, 2019 in Figure 5 , where the box plots depict the median and IQR of each action. Significance tests were performed using the Wilcoxon signed rank test or paired t-test as appropriate to assess if the performance distribution of the POMDP is significantly different from that of physicians. Tests with p-values < 0.05 were deemed significant.
Interestingly, the POMDP model's CIs become narrower over time, suggesting that it stabilizes with longer trajectories of observations. When only testing the POMDP model on a cohort of cases with nodules larger than 6 mm at baseline, the POMDP model improves the true negative rate (i.e., reduces the FP rate) while maintaining a TP rate comparable to the physicians. Markedly, precision is significantly improved using the POMDP model in this scenario. When testing on the cases with nodules smaller than 6 mm at baseline, initially the POMDP TN rate is lower than that of physicians' but improves over time. The TP rate and early prediction of cancer is significantly improved compared with physicians in post-screening. Precision is also significantly improved for all screenings. This comparison of cases that are typically easier to classify as cancerous due to a lager nodule size (i.e., ≥ 6 mm) demonstrates how our approach reduces FPs associated with lung cancer screening. Additionally, in the situation where IPNs are smaller (< 6 mm), our model still improves early prediction and overall precision. Box plots with the smaller than 6 mm and larger than 6 mm cohorts combined is presented in Figure 6 in the Appendix.
IV. DISCUSSION
The majority of individuals diagnosed with lung cancer have a low 5-year survival rate of 18% [31] . In sharp contrast, earlier detection of this cancer improves this statistic threefold to 56% [31] . While LDCT lung cancer screening aims to reduce mortality through earlier detection, the FP rate associated with IPNs remains high, with concomitant concerns of increased healthcare costs and unnecessary psychological burden for patients. To address this concern, we developed a POMDP for lung cancer screening, demonstrating simultaneous reduction in FPs and earlier cancer detection when compared to experts' performance. Maintaining a high TP rate while minimizing the FP rate is challenging given the correlation of nodule malignancy and size: larger nodules tend to be malignant; and conversely, nodules smaller than 6 mm are less likely to be cancerous. We improved the TN rate for nodules larger than 6 mm at baseline while maintaining a true positive rate on par with experts. When comparing our POMDP against physicians' predictions for cases with nodules smaller than 6 mm, improved true positive rate and precision overall were seen, while progressively increasing the TN rate (see Figure 5) .
Our POMDP uses a DBN to generate observations for a patient over time that are used to update its belief about lung cancer. We tested three variations of the POMDP, considering Table 4 . observations as being independent over time (i.e., an exhaustive search of every combination of observations), as probabilities of a static regression model, and as probabilities derived from a DBN. Representing these variables dynamically via the DBN improved model performance in comparison with the logistic regression model and performed similarly as exhaustive search. This analysis is presented in the Appendix in Table 16 ). Modeling observations using a dynamic model has two main advantages: first, a dynamic model can capture changes over time in these features, which in our opinion are potential indicators of lung cancer; and second, it allows effective scaling of the observation space with the incorporation of multiple temporal inputs. While considering temporal change is intuitive, many lung cancer risk models are ''static'' and use only the most current VOLUME 7, 2019 observations when calculating the likelihood of disease. Still, such risk models are useful in baseline assessment. The initial belief for each case in our POMDP uses the Tammemägi model [19] , instantiated using the subject's own demographic and clinical variables at baseline, updated with subsequent imaging observations.
The POMDP we designed makes use of a reward function learned through analysis of physicians' past decisions. We recently presented an adaptive maximum entropy inverse reinforcement learning (MaxEnt IRL) algorithm to inform a reward function in different cancers [12] . Using MaxEnt IRL, we established an optimization function explicitly modeling experts' actions. This strategy is different from other health-related POMDP applications [8] , [10] , [11] that typically employ cost functions based on quality-adjusted life years (QALYs), resource utilization, or other abstract metrics reflecting broader policy considerations. Building atop experts' prior actions, we take advantage of their experience and insights to integrate and weigh disparate information about a given individual; and by learning from multiple physicians and patients, we overcome potential biases. Yet curiously, per the diverging kappa score analysis, the POMDP is not fully replicating physicians' decisions. When it comes to early cancer prediction (e.g., predicting screening t 2 cancer from screening t 0 ), the POMDP outperforms experts, indicating that the model and associated reward function are discriminating between positive and negative cases in a different way. This difference may be attributed to the dynamic observation model used with this POMDP; when independent observations are instead assumed, we have found kappa scores to 1 in other domains, indicating high correlation between the model and experts' decisions [12] . Indeed, error analysis of the POMDP's FPs shows a different subset from the physicians: cases with smaller nodule sizes but more years of smoking and older baseline age are predicted as false positives by the POMDP. Early true positive cases share the same distributions, however, suggesting that a portion of POMDP false positives are early true positives. Table 2 illustrates this point in screening t 0 and post-screening for action a 0 : 71% of TPs are being predicted from a 0 for post-screening cases -but if compared with screening t 0 cancer cases, they would have been classified as FPs. Our previous work on predicting lung cancer in the LDCT screening setting showed encouraging results with earlier detection [16] . We showed that using a DBN trained on the NLST dataset we can match physicians' performance in predicting lung cancer, and in a portion of cases, in advance of the expert. But that method suffered from two limitations: first, the need to set an acceptable threshold for predicting lung cancer; and second, a decision-making process based solely on immediate outcomes without regard for longer-term benefits to the patient. We compared our current POMDP with our DBN [16] , reproducing it on the same cohort of subjects used in this paper (i.e., using identical training and test sets and the same stratified five-fold cross-validation analysis). Even when setting different probability thresholds to generate performance metrics (7 · 10 −6 , 0.01, and 0.01 for each screening time point of the NLST study), our new POMDP-based approach outperformed the earlier model in terms of reducing the FP rate and improving early lung cancer prediction (see Table 16 in Appendix).
Limitations of this work are around the real-world nature of cancer surveillance. It is unlikely that patients are screened at fixed one-year time intervals, for any number of reasons. As such, a discrete time model may not be well-suited for instances of imaging observations at irregular frequencies. Alternatively, a continuous time model may address this issue more accurately. We also used a simplified, expert-defined three-state cancer state space (e.g., no cancer, uncertain cancer, lung cancer); a more sophisticated approach would involve learning this state space from the data, which we plan to explore in the future. Likewise, the observation space of our POMDP model is discrete, whereas a continuous value space might yield further improvements. This method can be explored through the use of linear Gaussian conditional probability tables (CPTs) instead of discrete observational CPTs. Lastly, the number of cancer and non-cancer cases changes as a function of time (i.e., more cancer cases are found at baseline). We did not account for this imbalance during training other than performing a stratified five-fold cross-validation to obtain an unbiased estimate of the model. Similarly, other temporal studies have used a k-fold cross validation to assess model performance [32] - [36] . This data imbalance over time occurred as a result of simplifying our lung POMDP model to consider only cases reporting a single pulmonary nodule over the course of the trial. A more concrete analysis would include cases with multiple nodules over time. However, it was not possible to ascertain the history of individual nodules in patients with multiple nodules as the NLST dataset does not contain sufficient tracking information on nodules. Moreover, the imputation of observations by our DBN observational model at six month intervals, even though it reduces over-screening, is inferred rather than based on true screening observations. Future work includes conducting an external validation study of this NLST-based POMDP using data curated from our institution, expanding our observational model to consider multiple IPNs, as well as incorporating a richer set of imaging features derived from deep learning, which have demonstrated high classification performance in detecting malignant pulmonary nodules [37] , [38] .
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